At the frontline in ALK+ NSCLC: Raffaele Califano, MD, explores practical approaches and considerations when initiating TKI therapy #ALK #NSCLC #TKI #oncology #PeerVoice #MedEd peervoice.com/WAD?PromoCode=…

Five-year survival in pts with #SCLC treated with first-line carboplatin, etoposide, and atezolizumab (IMpower 133 to IMbrella A extension) Lung Cancer Journal. 3y OS rate 16%, 4y OS 13%, 5y OS 12%. Confirms long-term survival possible for subset of pts. lungcancerjournal.info/article/S0169-…

Come and join our fab, innovative team. Many opportunities in Cardiothoracic radiology. Please get in touch if interested 👍 #MFT #radiology #lungcancer #LCS

⏰ There's still time to sign up for this first-of-its-kind special workshop ESMO - Eur. Oncology (deadline 22 Sep). 🔖 ESMO Resilience Task Force Workshop: Leading for Better Mental Health, Well-being and Resilience of the Oncology Workforce For more info 👇 esmo.org/meeting-calend…

Are your patients one of the 160 delegates we already have registered for our 3rd Patient Conference? If not, there’s still time to tell them so they don’t miss out. 📧 [email protected] for info/register. We cover all travel costs for ALK+ pt plus 1 & hotel costs paid by

Superb lung session this morning with my friends Solange Peters Raffaele Califano .So many advances in lung...and superb amphitheatre full, a pleasure to exchange during this new ESMO Academy 24 ESMO - Eur. Oncology

Very proud to work with Carolina Reduzzi Eleonora Nicolò & International Society of Liquid Biopsy young group in this review on 20years of CTCs discovery #liquidbiopsy 🩺 Clinical significance 📊 Multi-analyte analysis ⏩ Future perspectives & clinical trials 💊 👇 sciencedirect.com/science/articl…

With FLAURA (osimertinib alone), FLAURA2 (osimertinib with chemotherapy), and MARIPOSA (amivantamab plus lazertinib) all now FDA approved 1L options for #EGFR NSCLC, how do we select the optimal regimen? Drs. Natasha Leighl, Tom Newsom-Davis and I discuss. iaslc.org/iaslc-news/lun…

Delighted to be working on this with many international colleagues Cynthia Eccles 💙 Alan McWilliam

Congratulations to the new Manchester Academic Health Science Centre Honorary Clinical Chairs healthinnovationmanchester.com/news/mancheste… Pietro Ivo D'Urso FRCS Division of Cancer Sciences

Mariposa study. Congratulations to the authors Raffaele Califano and colleagues and all those who contributed Philip Russell. ESMO - Eur. Oncology Manchester Cancer Research Centre

Pleased to share our review published in Trends in Molecular Medicine on cell-free and extrachromosomal DNA profiling of small cell lung cancer 👉 tinyurl.com/4x572nxf Based on my MSc Precision Medicine research project supervised by Dr Florent Mouliere at CRUK National Biomarker Centre CRUK Manchester Institute Division of Cancer Sciences

Grateful for the opportunity given by IASLC to join this inspiring group of people Looking forward to see their achievements!!

A good way to end a great program #WCLC24 IASLC Christian Rolfo

There is a rising incidence of early-onset (EO) cancers. Traditionally observed in adults over the age of 65, some solid tumors are now increasingly diagnosed in younger individuals under the age of 50 (annual percentage increase of 2.5% for pancreas, 5% for oropharynx, 8% for

Our multicentric study on carboplatin-etoposide rechallenge after 1L chemo-immunotherapy in ES-SCLC is finally out! Good old rechallenge remains a reliable option, regardless of the PFI (3-6 vs >6 months) The Christie NHS Manchester Cancer Research Centre Raffaele Califano journals.sagepub.com/doi/full/10.11…